Revenue operations vs the traditional approach: what actually beats what for healthcare and life sciences in the Nordics
A head-to-head on revenue operations versus the incumbent approach — where each wins, where each loses, and how to combine them. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Nordics.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Nordics. In this market, Nordic buyers reward directness, small buying committees, and a track record over a pitch, so the way you install revenue operations has to be shaped to that reality from day one.
The debate about revenue operations is often framed as replacement — new model wipes out old. That framing is wrong. The right question is where each approach wins.
Revenue operations wins on speed of learning, targeting precision, and cost per outcome. It is the function that owns the pipes between marketing, sales, and success, and it compounds in ways the traditional approach cannot match.
The traditional approach wins on relationship depth, brand consistency, and situations where the buyer has already self-identified. Ignoring that is why some teams' first revenue operations attempt underperforms — they replace the wrong parts.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Nordics it is compounded by the fact that reputation compounding, not campaign spend is what actually gates growth. Revenue operations is only useful here when it is pointed at both constraints at once.
Combine them deliberately. Use revenue operations to find and qualify; use the traditional approach to close and expand. The seam between them is where most pipeline is lost or won.
Metric to watch when running both: days-to-close and forecast accuracy, plus source attribution. The two approaches should not cannibalise each other; if they do, your handoff is broken.
The failure mode of running both is hiring RevOps to fix CRM instead of to own revenue — usually because the traditional team feels threatened and the new model is starved of context.
Companies that get this right end up with a hybrid engine that outperforms either pure model. Companies that pick one and evangelise it lose to the ones that combine.
Concretely for healthcare and life sciences in the Nordics: the healthcare teams that install this get past procurement instead of dying in it, and the Nordic teams that install this compound reputation faster than any paid channel could. That is the reason it is worth installing revenue operations deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
RevOps · healthcare · Nordics — answered
- Does revenue operations work for healthcare and life sciences in the Nordics?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Nordics, Nordic buyers reward directness, small buying committees, and a track record over a pitch. The healthcare teams that install this get past procurement instead of dying in it.
- Is revenue operations a replacement for the traditional approach?
- No — the two combine. Use the new model to find and qualify, the traditional model to close and expand.
- Where does the traditional approach still win?
- Relationship depth, brand-critical moments, and already-warm buyers.
- How do I run both without conflict?
- Clear handoff at a defined stage, shared metrics, and no source-based commissions that create tribal loyalty.
- What is the failure mode of combining them?
- Hiring RevOps to fix CRM instead of to own revenue — usually a broken handoff or a threatened incumbent team.
- What is the Nordics-specific pitfall when running revenue operations for healthcare?
- Importing a playbook that was built for another market. In the Nordics, Nordic buyers reward directness, small buying committees, and a track record over a pitch — the install has to reflect that.
Growth Broker editorial
Filed under revops · healthcare · nordics